TOP 1630

Drug Profile

TOP 1630

Alternative Names: TOP1630

Latest Information Update: 21 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TopiVert
  • Class Anti-inflammatories; Eye disorder therapies
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Protein kinase inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes

Highest Development Phases

  • Phase I/II Dry eyes

Most Recent Events

  • 15 Jun 2017 Topivert Pharma completes a phase II trial in Dry eyes in USA (NCT03088605)
  • 20 Feb 2017 Phase-I/II clinical trials in Dry eyes in USA (Topical) (NCT03088605)
  • 28 Nov 2016 US FDA approves IND application for TOP 1630 in Dry eye
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top